ניקסואה תשתתף בכנס הבריאות של בנק אוף אמריקה לשנת 2026

מונט-סן-גיבר, בלגיה – 30 באפריל 2026, GLOBE NEWSWIRE –

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המפתחת חלופות טיפול פורצות דרך לדום נשימה חסימתי בשינה (OSA), הודיעה היום כי החברה תשתתף בכנס הבריאות של Bank of America 2026 ביום רביעי, 13 במאי 2026. החברה צפויה להציג בשעה 17:15 שעון ET באותו יום באמצעות שידור אינטרנט.

Nyxoah to Participate in the Bank of America 2026 Healthcare Conference

Mont-Saint-Guibert, Belgium – April 30, 2026, GLOBE NEWSWIRE –

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Bank of America 2026 Healthcare Conference on Wednesday, May 13^th, 2026. The Company is scheduled to present at 5:15pm Eastern Time the same day via webcast.

A live audio webcast of Nyxoah’s presentation at the conference can be accessed through this LINK. The Company will be available for 1x1 meetings with institutional investors attending the event.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contacts:
Nyxoah
John Landry, CFO 
[email protected]

Rémi Renard 
Head of Investor Relations & Corporate Communication 
[email protected]

Attachment

• ENGLISH_BofAConference_Announcement PR

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire